

R  
ACD-2487  
2841

IMMUNOLOGY AND MOLECULAR EPIDEMIOLOGY  
OF HUMAN PAPILLOMAVIRUS IN  
CERVICAL CARCINOMA

CLOSED STACKS

BY  
NURHAYATI ZAINAL ABIDIN, B.Sc., M.Sc. (Western Illinois)  
DEPARTMENT OF GENETICS AND CELLULAR BIOLOGY  
FACULTY OF SCIENCE  
UNIVERSITY OF MALAYA

PERPUSTAKAAN UNIVERSITI MALAYA

THESIS PRESENTED FOR THE  
DEGREE OF DOCTOR OF PHILOSOPHY  
UNIVERSITY OF MALAYA  
KUALA LUMPUR  
(1996)

Perpustakaan Universiti Malaya



A506433210

26-06-2015

Dikiraikan pada..... 1975

No. Mikrofis..... 3

Jumlah Mikrofis..... 3

HAMSIAH BT. MOHAMAD ZAHARI

UPR

UNIT REPROGRAFI  
PERPUSTAKAAN UTAMA  
UNIVERSITI MALAYA

## ABSTRACT

Several human papillomavirus (HPV) types have been implicated in the development of cervical carcinoma worldwide. The use of molecular techniques have facilitated the detection and typing of HPV in cervical lesions of Malaysian patients. The analysis of HPV protein expression and immune response to HPV proteins on the other hand, have been made possible by the use of immunohistochemical and serological techniques.

DNA preparations from 40 cervical carcinoma, 30 normal cervical scrapes and 30 non-cervical specimens were analyzed by polymerase chain reaction (PCR) for the presence of HPV DNA. Subsequent Southern blot hybridization typing of PCR amplified HPV DNA using digoxigenin-labelled HPV 16 and 18 probes revealed the presence of HPV 16 in 57.5% and HPV 18 in 57.5% of cervical cancer specimens but none in the non-cervical cancer specimens. These viruses were also detected in 26% of the normal cervical scrapes.

Seventy four paraffin-embedded tissues of various cervical lesions were analyzed by *in situ* hybridization using digoxigenin-labelled probes for HPV 16 and 18 DNA sequences. HPV DNA was found in 76% of the cervical tissues. The prevalence of HPV DNA sequences increased with severity of the CIN lesions ranging from 25% in CIN 1 and 67% in CIN 2 to 85% in CIN 3/CIS. HPV DNA was detected in 80% of both adenocarcinoma and squamous cell carcinoma cases. Analysis of the data by viral types revealed that HPV 16 prevailed in 25% of CIN 1, 67% of CIN 2, 55% of CIN 3/CIS, 20% of adenocarcinomas and 67% of squamous cell carcinomas. HPV 18 was detected in 25% of CIN 1, 53% of CIN 2, 85% of CIN 3/CIS, 80% of adenocarcinomas and 61% of squamous cell carcinomas. The detection rate of HPV DNA increased

from 25% in low grade lesions (CIN 1) to 77% in high grade lesions (CIN 2 and CIN 3/CIS).

Combined data indicate that the prevalence of HPV 16 DNA (57.9%) did not differ significantly from that of HPV 18 DNA (64%) in all cervical lesions analyzed. In squamous cell carcinomas HPV 16 was prevalent as frequently as HPV 18 DNA but in adenocarcinoma HPV 18 DNA (80%) was detected more often than HPV 16 DNA (20%). Mixed infections with both HPV types were present in all histological grades of cervical lesions. Mixed infections occurred more often than single infections with either type.

Immunohistochemical analysis revealed that the expression of HPV 18 E6 and HPV 16 L1 proteins in cervical lesions. The expression of HPV 18 E6 protein increased with enhanced severity of the cervical lesions, ranging from 53.3% of CIN 2 to 90% of CIN 3/CIS, 100% of adenocarcinoma and 83.3% of squamous cell carcinoma cases. The protein was not detectable in low grade lesions but increased to 75.7% of the high grade lesions and continued to be highly expressed in invasive carcinomas. This reflects the higher E6 transforming activity in the more severe lesions.

Of the 74 cervical lesions examined, 52.7% exhibited the presence of HPV 16 L1 protein. The protein was expressed in 26.6% of CIN 2, 50% of CIN 3/CIS, 80% of adenocarcinoma and 70% of squamous cell carcinoma cases. An increase in the L1 protein positivities was observed with severity of the cervical lesions indicating that the L1 gene may not be totally disrupted with integration of the HPV DNA into the host genome.

Serologic response to HPV 16 and 18 in sera obtained from 80 cervical cancer patients, 32 healthy pregnant women and 30 healthy university students were evaluated with ELISA assays using six synthetic peptides, synthesized based on

sequences deduced from the early and late regions of HPV 16 and 18. Anti-HPV antibodies were found in all three groups of women studied. None of the antibodies to peptides L1:13, L1:30, L2:49 and E7:5 of HPV 16 seemed to be sufficiently disease specific to be used as markers for cervical cancer. Although anti-HPV 16 E7:5 antibodies were also prevalent in healthy subjects, the data revealed that the HPV 16 E7 protein was produced in elevated amounts in cervical cancer patients. This reflects the higher E7 transforming activity in these patients.

Anti-HPV 16 E2:245 IgA and anti-HPV 18 E2:245 IgA and IgG antibodies seemed to have specificity for cervical cancer and thus have the potential to be used as markers for the disease. The higher prevalence of anti-E2:245 antibodies in cervical cancer patients suggest a role of the E2 protein in cervical carcinogenesis.

The increasing association of HPV 16 and 18 with enhanced severity of the cervical lesions suggest that these high risk oncogenic viruses have a role in the development and progression of cervical cancer. However since molecular and serological evidence have revealed that HPV 16 and 18 infections are widespread among healthy Malaysian females, it can therefore be deduced that infection with HPV 16 and 18 per se is important but may not represent a sufficient etiological component for cervical cancer development.

## ABSTRAK

Beberapa jenis virus papiloma manusia (HPV) telah dikaitkan dengan karsinoma serviks di seluruh dunia. Penggunaan pelbagai teknik molekul telah mengesan dan megenalpasti jenis-jenis HPV yang hadir di dalam lesi servikal pesakit-pesakit di Malaysia. Ekspresi protein HPV dan gerakbalas imun terhadap protein-protein HPV telah dikaji dengan menggunakan teknik-teknik imunohistokimia dan serologi.

DNA dari 40 sampel karsinoma serviks, 30 sampel kikisan serviks normal dan 30 sampel bukan serviks telah dikaji untuk mengesan kehadiran DNA HPV dengan menggunakan teknik rantaian polimeras (PCR). Hibridisasi blot Southern ke atas amplikon HPV DNA telah mengenalpasti kehadiran HPV 16 dalam 57.5% dan HPV 18 dalam 57.5% dari spesimen-spesimen kanser serviks tetapi tidak dalam sampel-sampel bukan serviks. Virus-virus ini juga telah dikesan dalam 26% dari kikisan serviks normal.

Sejumlah 74 tisu parafin yang terdiri dari beberapa gred lesi serviks telah dikaji dengan menggunakan teknik hibridisasi *in situ*. Kajian ini telah menggunakan prob berlabel digoxigenin yang spesifik untuk HPV 16 dan HPV 18. DNA HPV telah berjaya dikesan dalam 76% dari kesemua lesi servikal yang dikaji. Kehadiran DNA HPV didapati meningkat dengan keterukan lesi, iaitu dari 25% untuk CIN 1, 67% untuk CIN 2 kepada 85% untuk CIN 3/CIS. DNA HPV juga telah dikesan dalam 80% dari kes-kes adenokarsinoma dan karsinoma sel skuamus. HPV 16 telah dikenalpasti dalam sebanyak 25% dari CIN 1, 67% dari CIN 2, 55% dari CIN 3/CIS, 80% dari adenokarsinoma dan 67% dari karsinoma sel skuamus. HPV 18 pula telah dikesan dalam 67% dari CIN 1, 53% dari CIN 2, 85% dari CIN 3/CIS, 80% dari adenokarsinoma dan 61% dari karsinoma sel skuamus. Pengesanan DNA HPV

meningkat dari 25% di dalam lesi gred rendah (CIN 1) kepada 77% di dalam lesi gred tinggi (CIN 2 dan CIN 3/CIS).

Gabungan data menunjukkan bahawa kadar pengesanan DNA HPV 16 (57.9%) tidak banyak berbeza dari kadar pengesanan DNA HPV 18 (64%) dalam kesemua lesi serviks yang dikaji. Bagi karsinoma sel skuamus, DNA HPV 16 dan HPV 18 telah dikesan dengan kadar yang sama. Walaubagaimanpun, DNA HPV 18 (80%) telah lebih kerap dikesan dalam adenokarsinoma berbanding dengan DNA HPV 16 (20%). Infeksi bercampur dan kehadiran kedua-dua jenis HPV telah dikesan dalam kesemua gred lesi serviks yang dikaji. Kecuali adenokarsinoma, infeksi bercampur adalah lebih kerap berlaku berbanding dengan infeksi tunggal dengan mana-mana satu jenis HPV.

Analisis imunohistokimia telah mengesan ekspresi protein E6 dari HPV 18 dan protein L1 dari HPV 16. Kadar ekspresi protein E6 didapati meningkat dengan keterukan lesi iaitu dari 53.3% untuk CIN 2 kepada 90% untuk CIN 3/CIS, 100% untuk adenokarsinoma dan 83.3% untuk karsinoma sel skuamus. Protein tersebut tidak dapat dikesan dalam lesi gred rendah tetapi meningkat kepada 75.7% dalam lesi gred tinggi dan terus dikesan dengan kadar yang tinggi dalam karsinoma. Ini menunjukkan bahawa aktiviti transformasi oleh protein E6 adalah tinggi dalam lesi-lesi yang teruk.

Daripada 74 lesi serviksl yang dikaji, 52.7% telah menunjukkan kehadiran protein L1 dari HPV 16. Protein ini dikesan dalam 26.6% dari lesi CIN 2, 50% dari lesi CIN 3/CIS, 80% dari adenokarsinoma dan 70% dari karsinoma sel skuamus. Kadar pengesanan protein L1 meningkat dengan keterukan lesi. Ini membuktikan bahawa tidak semua gen L1 yang terhapus semasa proses integrasi DNA HPV ke dalam genom perumah.

Gerak balas serologi terhadap HPV 16 dan HPV 18 dalam serum yang diperolehi dari 80 orang pesakit karsinoma serviks, 32 orang wanita hamil yang sihat dan 30 orang pelajar universiti telah dikajiselidik dengan menggunakan teknik ELISA dengan menggunakan enam jenis peptida sintetik. Peptida-peptida sintetik tersebut telah dibuat berasaskan jujukan gen dari HPV 16 dan HPV 18. Antibodi-antibodi HPV telah dikesan dalam ketiga-tiga kumpulan wanita yang dikaji. Kajian menunjukkan bahawa kehadiran antibodi-antibodi terhadap protein L1:13., L1:30, L2:49 dan E7:5 dari HPV 16 tidak spesifik kepada penyakit karsinoma serviks dan dengan itu tidak sesuai untuk dijadikan penanda bagi penyakit tersebut. Data yang diperolehi menunjukkan bahawa walaupun antibodi terhadap protein E7:5 dari HPV 16 telah dapat dikesan dalam serum wanita-wanita sihat, protein tersebut telah dihasilkan dengan kuantiti yang lebih banyak dalam pesakit-pesakit karsinoma serviks. Ini membuktikan bahawa aktiviti transformasi oleh protein E7 adalah tinggi dalam pesakit-pesakit karsinoma serviks. Kajian mendapati bahawa antibodi IgA terhadap protein E2:245 dari HPV 16 dan antibodi IgA dan IgG terhadap protein E2:245 dari HPV 18 adalah spesifik kepada karsinoma serviks dan dengan itu berpotensi untuk dijadikan penanda bagi penyakit tersebut. Kehadiran antibodi-antibodi terhadap protein E2:245 dengan kadar yang lebih tinggi di kalangan pesakit-pesakit karsinoma serviks mencadangkan penglibatan protein E2 dalam pembentukan karsinoma tersebut.

Peningkatan kadar pengesanan HPV 16 dan HPV 18 dengan keterukan lesi prekursor dan karsinoma serviks mungkin menunjukkan penglibatan virus onkogen risiko tinggi ini dalam pembentukan dan perkembangan kanser serviks. Adalah wajar jika disimpulkan bahawa jangkitan oleh HPV 16 dan HPV 18 adalah penting tetapi ianya bukan faktor tunggal dalam pembentukan karsinoma serviks kerana penemuan

kajian molekul dan serologi telah menunjukkan bahawa jangkitan oleh HPV 16 dan HPV 18 adalah berleluasa dikalangan wanita-wanita di Malaysia.

## ACKNOWLEDGEMENTS

I acknowledge with sincere appreciation the guidance and support of my supervisor, Professor M. S. Yadav, throughout the entire course of this study. Utmost gratitude also goes to Dr. Joshua M. Daniels (Melaka General Hospital); Mr. Chang Farn Shing (Melaka General Hospital); Associate Professor Abdul Aziz Yahya (Hospital Kuala Lumpur); Professor Sivanesaratnam (University Hospital, Kuala Lumpur); Dr. K. Kutty (Subang Jaya Medical Centre, Selangor) and Dr. Chan (Sultanah Aminah Hospital, Johor Bharu) for their kind assistance in providing the samples used in this study.

I am equally grateful to Dr. Joakim Dillner (Sweden) for the gift of the synthetic peptides; Dr. E. M. deVilliers (Germany) for the gift of HPV 16 and HPV 18-containing plasmids pBR 322; Dr. Hans Ulrich Bernard (Singapore) for the gift of CaSki and SiHa cell lines and Dr. Margaret Stanley (England) for the gift of HPV 16 L1 monoclonal antibody.

My sincere gratitude is extended to Dr. Norhanom, the head of the project "New Tools for the Early Diagnosis of Gynaecological Neoplasm"; Dr. Chong Ving Ching for his advice on the statistics; Anil for his technical assistance and for being a special friend; Rakesh and Ashril for their technical assistance and Nirmala for collecting the samples. Likewise I would like to thank all my friends, Lin, Subra, Selva, Vimala and Meow Lin for their friendship and support.

Last but not least, I would like to specially acknowledge my beloved husband, Khairuzzaman for his assistance in typing the manuscript and mostly for his patience and understanding, for his unfailing love and constant support; my children, Farah Inaz and Izzat Iskandar for being a tremendous joy and inspiration; my parents for

their endless love, faith and encouragement and my family, Diana, Azman, Imran, Siti and Izham for their understanding and moral support.

The work was funded by the University of Malaya (PJP 231/93) and Ministry of Science, Technology and Environment, Malaysia (Grant no: 3/092/01 (27)).

## TABLE OF CONTENTS

<b>ABSTRACT</b>	.....	i
<b>ABSTRAK</b>	.....	iv
<b>ACKNOWLEDGEMENT</b>	.....	viii
<b>TABLE OF CONTENTS</b>	.....	x
<b>LIST OF ABBREVIATIONS</b>	.....	xv
<b>LIST OF TABLES</b>	.....	xvii
<b>LIST OF FIGURES</b>	.....	xix
<b>CHAPTER 1 - INTRODUCTION</b>	.....	1
<b>CHAPTER 2 - LITERATURE REVIEW</b>	.....	
2.1      The Cervix	.....	5
2.1.1     Anatomy of the Cervix	.....	5
2.1.2     Normal Histology	.....	6
2.2      Cervical cancer	.....	7
2.2.1     Preinvasive cervical lesions	.....	7
2.2.2     International classification of cervical carcinoma	.....	8
2.2.3     Histological types of cervical carcinoma	.....	11
2.2.4     Pathology of cervical carcinoma	.....	11
2.2.5     Spread of the tumour	.....	11
2.2.6     Clinical symptoms	.....	12
2.3      Treatment and Prevention	.....	13
2.3.1     Methods of diagnosis	.....	13
2.3.2     Treatment of CIN/CIS	.....	14
2.3.3     Treatment of cervical carcinoma	.....	15
2.4      Epidemiology of cervical cancer	.....	16
2.4.1     Age at first sexual intercourse	.....	16
2.4.2     Number of sexual partners	.....	16
2.4.3     Parity	.....	17
2.4.4     Characteristics of the male sexual partner	.....	18
2.4.5     Socioeconomic status	.....	19
2.4.6     Cigarette smoking	.....	19
2.4.7     Nutrition	.....	20
2.4.8     Oral contraceptive	.....	21
2.5      Papillomaviruses	.....	22
2.5.1     Genome structure and organization	.....	23
2.5.2     Viral transcription	.....	27
2.5.3     Viral replication	.....	30
2.5.4     Classification of human papillomaviruses	.....	31

2.5.5	Clinical manifestations of HPV infections	.....	31
2.5.6	HPV infections of the genital tract	.....	35
2.5.7	HPV and cervical carcinoma	.....	36
2.6	Immune response to HPV	.....	38
2.6.1	Humoral response	.....	38
2.6.1.1	Synthetic peptides	.....	40
2.6.1.2	Fusion proteins	.....	41
2.6.2	Cell mediated immunity	.....	42
2.6.2.1	Natural killer (NK) cells	.....	43
2.6.2.2	Langerhans' cells	.....	44
2.6.2.3	T cell response	.....	45
2.7	Detection of papillomavirus infection	.....	46
2.7.1	Clinical examination	.....	46
2.7.2	Nucleic acid hybridization	.....	47
2.7.2.1	Southern blot hybridization	.....	48
2.7.2.2	In situ hybridization	.....	49
2.7.2.3	Non-radioactive probe	.....	49
2.7.3	Polymerase chain reaction technique (PCR)	.....	51
2.7.4	Enzyme-Linked Immunosorbent Assay (ELISA)	.....	53
2.7.5	Immunohistochemistry	.....	54

### CHAPTER 3 - MATERIALS AND METHODS

3.1	Detection of HPV 16 and 18 DNA in clinical samples	.....	56
3.1.1	Clinical samples	.....	56
3.1.1.1	Fresh frozen invasive cervical carcinoma biopsies	.....	56
3.1.1.2	Cervical scrapes	.....	56
3.1.1.3	Noncervical DNA samples	.....	56
3.1.2	Primers used for the amplification of the $\beta$ -globin gene	.....	57
3.1.3	Degenerate primers used for the amplification of HPV sequences	.....	57
3.1.4	Plasmids	.....	58
3.1.4.1	Plasmids isolation	.....	59
3.1.5	Cell lines	.....	60
3.1.5.1	Reviving and culturing of cells	.....	60
3.1.5.2	Cryopreservation of cells	.....	61
3.1.6	DNA extraction	.....	61
3.1.6.1	Quantification of DNA samples	.....	62
3.1.7	Polymerase chain reaction	.....	63
3.1.7.1	PCR amplification of the $\beta$ -globin gene	.....	63
3.2.7.2	PCR amplification of the HPV DNA	.....	64
3.1.8	Agarose gel electrophoresis	.....	64
3.1.9	Non-radioactive HPV DNA probe preparation and labelling	.....	65
3.1.10	Southern transfer of PCR amplified products	.....	66
3.1.11	Non-radioactive hybridization	.....	67
3.1.12	Detection of hybrids on nylon membranes	.....	68

3.2	Detection of HPV 16 and 18 DNA by in situ hybridization	....	70
3.2.1	Paraffin embedded cervical biopsies	....	70
3.2.2	Pretreatment of slides	....	70
3.2.3	Culturing cell lines on slides	....	71
3.2.4	In situ hybridization	....	72
3.2.5	Detection of hybrids on slides	....	73
3.2.6	Statistical analysis	....	74
3.3	Detection of HPV proteins	....	74
3.3.1	Monoclonal antibodies	....	74
3.3.2	Immunohistochemistry	....	74
3.3.3	Statistical analysis	....	76
3.4	Serology to HPV	....	76
3.4.1	Peptides	....	76
3.4.2	Blood samples	....	76
3.4.3	Enzyme-Linked Immunosorbent Assay	....	77
3.4.4	Statistical analysis	....	79

## CHAPTER 4 - RESULTS

4.1	Detection of HPV DNA by PCR and Southern blot hybridization	....	80
4.1.1	PCR amplification of HPV DNA extracted from cervical carcinoma biopsy tissues	....	80
4.1.2	Southern blot hybridization typing of HPV DNA from cervical carcinoma biopsy tissues	....	81
4.1.3	PCR amplification of HPV DNA from normal cervical scrapes	....	81
4.1.4	Southern blot hybridization typing of HPV from normal cervical scrapes	....	82
4.1.5	PCR amplification of HPV DNA from non-cervical specimens	....	82
4.1.6	Southern blot hybridization typing of HPV DNA from non-cervical specimens	....	82
4.1.7	Controls for PCR and Southern blot hybridization	....	83
4.2	( In situ hybridization detection of HPV 16 and HPV 18 in cervical lesions	....	89
4.2.1	Detection of HPV 16 and 18 DNA in CIN 1	....	89
4.2.2	Detection of HPV 16 and 18 DNA in CIN 2	....	89
4.2.3	Detection of HPV 16 and 18 DNA in CIN 3/CIS	....	90
4.2.4	Detection of HPV 16 and 18 DNA in invasive cervical carcinomas )	....	90
4.3	Prevalence of HPV 16 and 18 DNA in CIN and invasive caeival lesions as detected by PCR, Southern blot hybridization and in situ hybridization	....	91
4.3.1	Occurrence of single and mixed infections with HPV 16 and 18 in cervical lesions	....	92
4.3.2	Age of patients at diagnosis and histologic features of cervical lesions	....	93

4.3.3	Prevalence of HPV DNA and age of patients	....	93
4.4	Detection of HPV antigens by immunohistochemistry	....	104
4.4.1	Correlation between cervical histology and the detection frequencies of HPV 18 E6 protein	....	104
4.4.1.1	Correlation between the expression of E6 protein and the presence of HPV 18 DNA	....	105
4.4.1.2	Topographical distribution of HPV 18 E6 protein in cervical lesions	....	105
4.4.1.3	Distribution of HPV 18 E6 protein in CIN 2	....	106
4.4.1.4	Distribution of HPV 18 E6 protein in CIN 3/CIS	....	106
4.4.1.5	Distribution of HPV 18 E6 protein in invasive carcinoma	....	107
4.4.1.6	Intracellular localization of HPV 16 E6 protein in CIN and invasive carcinoma )	....	107
4.4.2	Correlation between cervical histology and the detection frequencies of HPV 16 L1 protein	....	115
4.4.2.1	Correlation between the expression of the HPV 16 L1 protein and the presence of HPV 16 DNA	....	116
4.4.2.2	Topographical distribution of HPV 16 L1 protein in cervical lesions	....	116
4.4.2.3	Distribution of HPV 16 L1 protein in CIN 1	....	117
4.4.2.4	Distribution of HPV 16 L1 protein in CIN 2	....	118
4.4.2.5	Distribution of HPV 16 L1 protein in CIN 3/CIS	....	118
4.4.2.6	Distribution of HPV 16 L1 protein in invasive carcinoma	....	118
4.5	Serology to HPV	....	127
4.5.1	Immune response to HPV 16 L1:13 peptide	....	127
4.5.2	Immune response to HPV 16 L1:30 peptide	....	134
4.5.3	Immune response to HPV 16 L2:49 peptide	....	140
4.5.4	Immune response to HPV 16 E2:245 peptide	....	146
4.5.5	Immune response to HPV 16 E7:5 peptide	....	152
4.5.6	Immune response to HPV 18 E2:245 peptide	....	158

## CHAPTER 5 - DISCUSSION

5.1	Polymerase chain reaction and Southern blot hybridization	....	164
5.2	In situ hybridization	....	168
5.2.1	Distribution of HPV DNA within CIN lesions as detected by in situ hybridization	....	170
5.2.2	Distribution of HPV DNA within invasive cervical lesions as detected by in situ hybridization	....	172
5.3	Prevalence of HPV 16 and 18 in cervical lesions as determined by in situ hybridization and PCR-Southern blot hybridization	....	173
5.3.1	Prevalence of HPV 16 and 18 in CIN	....	173
5.3.2	Prevalence of HPV 16 and 18 DNA in invasive carcinoma	....	177
5.3.3	HPV genotype and cell patterns	....	179
5.3.4	Occurrence of mixed infections in cervical lesions	....	180

5.3.5	HPV-negative invasive carcinoma	.....	182
5.3.6	Age of patients at diagnosis and histologic of cervical lesions	.....	183
5.3.7	Prevalence of HPV 16 and 18 in relation to the age of patients	.....	183
5.3.8	Detection of HPV 16 and 18 DNA in normal cervical scrapes	.....	184
5.4	Immunohistochemical detection of HPV antigens	.....	187
5.4.1	Detection HPV 18 E6 antigen in cervical lesions	.....	187
5.4.1.1	Distribution of HPV 18 E6 protein in CIN	.....	188
5.4.1.2	Distribution of HPV 18 E6 protein in cervical cancer	.....	190
5.4.2	Detection of HPV 16 L1 protein in cervical lesions	.....	193
5.4.2.1	Detection of HPV 16 L1 protein in CIN	.....	193
5.4.2.2	Detection of HPV 16 L1 protein in invasive carcinoma	.....	195
5.5	Serology to HPV	.....	199
5.5.1	Immune response to HPV 16 L1:13 and L1:30 peptides	.....	201
5.5.2	Immune response to the L2 peptide	.....	202
5.5.3	Immune response to HPV 16 E7:5 peptide	.....	204
5.5.4	Immune response to HPV 16 and 18 E2:245 peptide	.....	206
5.5.5	Immune response of pregnant women to HPV antigen	.....	209
5.5.6	Immune response of healthy university students to HPV antigens	.....	212
<b>CHAPTER 6 - CONCLUSION</b>		.....	214
<b>BIBLIOGRAPHY</b>		.....	218
<b>APPENDIX</b>		.....	252

## LIST OF ABBREVIATIONS

%	:	percentage
$\mu$	:	micron
$^{\circ}\text{C}$	:	degree centigrade
$\mu\text{g}$	:	microgram
$\mu\text{l}$	:	microlitre
bp	:	base pair
CIN	:	cervical intraepithelial neoplasia
CIS	:	carcinoma in situ
cm	:	centimeter
dATP	:	deoxyadenosine triphosphate
dCTP	:	deoxycytidine triphosphate
ddH <sub>2</sub> O	:	deionized distilled water
dGTP	:	deoxyguanosine triphosphate
DIG	:	digoxigenin
DNA	:	deoxyribonuclease
dNTP	:	deoxynucleotide triphosphate
dTTP	:	deoxythymidine triphosphate
EDTA	:	ethylenediamine tetraacetic acid
ELISA	:	enzyme-linked immunosorbent acid
g	:	gram
HEPES	:	hydroxyethylpiperazine ethanesulfonic acid
kb	:	kilobase
M	:	molar
mg	:	milligram
ml	:	millilitre
MOPs	:	3-N-morpholino-propanesulfonic acid
NBT	:	4-nitroblue tetrazolium chloride
ng	:	nanogram
PBS	:	phosphate buffered saline
RNase	:	ribonuclease

rpm	:	revolution per minute
SCC	:	squamous cell carcinoma
SDS	:	sodium dodecyl sulphate
TBE	:	tris-borate-EDTA
UV	:	ultraviolet
w/v	:	weight per volume
WHO	:	World Health Organization
CO <sub>2</sub>	:	carbon dioxide
FCS	:	fetal calf serum
OD	:	optical density
nm	:	nanometer
PCR	:	polymerase chain reaction
pmole	:	picomole
U	:	units
ADC	:	adenocarcinoma
CS	:	lamb serum
PBS-T	:	phosphate buffered saline-tween
PCR-SB	:	polymerase chain reaction-Southern blot hybridization
ISH	:	in situ hybridization
ORF	:	open reading frame
FIGO	:	Federation of Gynaecology and Obstetrics
HPV	:	human papillomavirus
E	:	early region
L	:	late region
LCR	:	long control region
kDa	:	kilodalton
BPV	:	bovine papillomavirus
RNA	:	ribonucleic acid
MHC	:	major histocompatibility complex
NK	:	natural killer cells
Tm	:	melting point

## LIST OF TABLES

Tables	Subjects	Page
2.1.	Distribution of HPV types by the degree of genetic relatedness	33
2.2.	The human papillomavirus-induced cutaneous and mucosal lesions	34
3.1..	Reaction mix for the amplification of $\beta$ -globin sequences in the DNA obtained from fresh frozen biopsy tissues, pap smears and noncervical samples	64
3.2.	Reaction mix for the amplification of HPV DNA sequen	64
3.3.	Reaction mix for DNA probe labelling	66
3.4.	Synthetic peptides of HPV 16 and HPV 18	76
4.1.	Distribution of HPV 16 and 18 in various cervical and non-cervical tissues as determined by PCR and Southern blot hybridization	84
4.2.	Distribution of HPV 16 and HPV 18 in CIN lesions as determined by <i>in situ</i> hybridization	94
4.3.	Overall frequency of HPV 16 and HPV 18 DNA in cervical lesions as determined by PCR-Southern blot hybridization (PCR-SB) and <i>in situ</i> hybridization (ISH)	101
4.4.	Distribution of HPV 16 and HPV 18 in preinvasive lesions	102
4.5.	Correlation of age of patients at diagnosis and type of cervical lesions	102
4.6.	Correlation of age of patients at diagnosis and HPV HPV genotype	103
4.7.	Detection of HPV 18 E6 protein in relation to the status of HPV DNA in the cervical intrepithelial neoplasia and cervical cancer	108
4.8.	Intracellular localization of HPV 18 E6 protein cervical lesions as determined by immunohistochemistry	115
4.9.	Detection of HPV 16 L1 protein according to the status of HPV 16 DNA in cervical intraepithelial neoplasia and cervical cancer	120
4.10.	Detection of antibodies against HPV 16 L1:13 in (a) cervical cancer patients (b) healthy pregnant women (c) healthy university students	130
4.11.	Detection of antibodies against HPV 16 L1:30 in (a) cervical cancer patients (b) healthy pregnant women (c) healthy university students	136
4.12.	Detection of antibodies against HPV 16 L2:49 in (a) cervical cancer patients (b) healthy pregnant	

	women (c) healthy university students	142
4.13.	Detection of antibodies against HPV 16 E2:245 in (a) cervical cancer patients (b) healthy pregnant women (c) healthy university students	148
4.14.	Detection of antibodies against HPV 16 E7:5 in (a) cervical cancer patients (b) healthy pregnant women (c) healthy university students	154
4.15.	Detection of antibodies against HPV 18 E2:245 in (a) cervical cancer patients (b) healthy pregnant women (c) healthy university students	160

## LIST OF FIGURES

Figures	Subject	Page
2.1.	Schematic representation of cervical cancer precursors - CIN 1,2, 3 and CIS	10
2.2.	Genomic organization of HPV 16	29
4.1.	Photograph of a 2% agarose gel showing PCR amplified HPV DNA with primers MY11 and MY09	85
4.2.	Photograph of corresponding Southern blot hybridization of PCR amplified product to digoxigenin-labelled HPV 16 DNA probe	86
4.3.	Photograph of a 2% agarose gel showing PCR amplified HPV DNA with primers MY11 and MY09	86
4.4.	Photograph of corresponding Southern blot hybridization of PCR amplified product to digoxigenin-labelled HPV 18 DNA probe	87
4.5.	In situ hybridization analysis of paraffin-embedded CIN 1 tissue using digoxigenin-labelled HPV 16 and 18 DNA probes	88
4.6.	In situ hybridization of HPV 16 and 18 DNA in CIN 2 tissues	95
4.7.	Localization of HPV 16 and HPV 18 DNA in nucleus of cells of CIN 3/CIS tissues	96
4.8.	Presence of HPV DNA in squamous cell carcinoma of the cervix	97
4.9.	DIG detection of HPV 16 genome in HPV-16 carrying CaSki cells fixed onto glass slides	98
4.10.	DIG detection of HPV 18 genome in HPV 18-carrying HeLa cells grown onto glass slides	99
4.11.	Distribution of HPV types according to age groups of patients with cervical lesions	100
4.12.	Correlation between HPV 18 E6 positivity and grades of cervical lesions	103
4.13.	Correlation between the expression of HPV 18 E6 oncoprotein and the detection rate of HPV 18 DNA in CIN lesions and cervical cancer	109
4.14.	Detection of HPV 18 E6 protein in HPV 18-containing HeLa cells using the Labelled Streptavidin Biotin (LSAB) peroxidase, the AEC substrate system and anti-HPV 18 E6 monoclonal antibody (diluted 1:80)	110
4.15.	Immunohistochemical detection of HPV 18 E6 protein in paraffin-embedded CIN 2 tissue	111
4.16.	Detection of HPV 18 E6 protein in cells of CIN 3/CIS	112
4.17.	Localization of HPV 18 E6 protein in the intranuclear and cytoplasmic regions of cells of squamous cell carcinoma	113
4.18.	Correlation between the expression of HPV 16 L1 protein and the detection rate of HPV 16 DNA in	114

	CIN lesions and cervical cancer	...	121
4.19.	HPV 16-containing CaSki cells showing no staining to anti-HPV 16 L1 monoclonal antibody (dilution 1:40)	...	122
4.20.	Presence of HPV 16 L1 protein in cells of CIN 2	...	123
4.21.	Distribution of HPV 16 L1 protein in cells of CIN 3/CIS	...	124
4.22a.	Intranuclear localization of HPV 16 L1 protein in cells of adenocarcinoma	...	125
4.22b.	Localization of HPV 16 L1 protein in the nucleus of cells of squamous cell carcinoma	...	126
4.23a.	IgA reactivity to HPV 16 L1:13	...	131
4.23b.	IgG reactivity to HPV 16 L1:13	...	132
4.23c.	IgM reactivity to HPV 16 L1:13	...	133
4.24a.	IgA reactivity to HPV 16 L1:30	...	137
4.24b.	IgG reactivity to HPV 16 L1:30	...	138
4.24c.	IgM reactivity to HPV 16 L1:30	...	139
4.25a.	IgA reactivity to HPV 16 L2:49	...	143
4.25b.	IgG reactivity to HPV 16 L2:49	...	144
4.25c.	IgM reactivity to HPV 16 L2:49	...	145
4.26a.	IgA reactivity to HPV 16 E2:245	...	149
4.26b.	IgG reactivity to HPV 16 E2:245	...	150
4.26c.	IgM reactivity to HPV 16 E2:245	...	151
4.27a.	IgA reactivity to HPV 16 E7:5	...	155
4.27b.	IgG reactivity to HPV 16 E7:5	...	156
4.27c.	IgM reactivity to HPV 16 E7:5	...	157
4.28a.	IgA reactivity to HPV 18 E2:245	...	161
4.28b.	IgG reactivity to HPV 18 E2:245	...	162
4.28c.	IgM reactivity to HPV 18 E2:245	...	163